venBio Partners Closes Second Life Sciences Venture Capital Fund, at $315M

venbiovenBio Partners LLC, a global life sciences investment firm, closed its second venture capital fund, at approximately $315m.

Anchored by major investments from three strategic limited partners – Amgen, Merck, and Baxalta – along with a group of financial Limited Partners, the venBio Global Strategic Fund II exceeded its target of $250m.

Led by managing partners Robert Adelman, M.D., and Corey Goodman, Ph.D., venBio is a life sciences investment firm building medicines and technologies with a focus on novel therapeutics for unmet medical needs.
To date the firm has manage two strategic funds which have invested in 14 companies including: Cytos (now KURN), Aragon (acquired by J&J), Solstice, Labrys (acquired by Teva), Seragon (acquired by Roche/Genentech), Aurinia (AUPH), Heart Metabolics, Metacrine, Alexo, Precision Biosciences, Checkmate, Adheren, Apellis, and Nabriva (NBRV).

venBio has also announced new additions to the team:
– Aaron Royston, M.D., previously a senior associate at Vivo Capital, as principal, and
– Jaume Pons, Ph.D., currently CEO of Alexo Therapeutics, a venBio portfolio immuno-oncology company, as venture partner.

In addition to the San Francisco team, venBio is also overseen by Behzad Aghazadeh, Ph.D., a managing partner in New York.



Join the discussion